
Insufficient Sleep and Late Bedtimes: Early Puberty Risk?
Not getting enough sleep and going to bed late were associated with a higher risk for central precocious puberty, particularly in girls. Girls with this condition often had serious sleep issues 3.5 years before puberty began.
METHODOLOGY:
Researchers analyzed data from a prospective cohort of 2238 children (1492 girls aged 6-14 years and 746 boys aged 9-17 years) recruited from four hospitals in Taiwan.
Sleep parameters such as duration of sleep, later bedtimes, sleep onset time, and overall sleep quality were assessed using the Pittsburgh Sleep Quality Index. A score greater than 5 represented poor sleep quality.
Insufficient sleep was defined as sleep lasting less than 9 hours for children younger than 12 years and less than 8 hours for adolescents, and late bedtime was defined as going to bed after 9 PM for children younger than 12 years and after 10 PM for adolescents.
Children were followed up every 3 months.
Central precocious puberty was diagnosed on the basis of early development of secondary sexual characteristics, advanced bone age, and specific hormonal criteria; children with peripheral precocious puberty or missing data were excluded.
TAKEAWAY:
Overall, 742 children had central precocious puberty, and 1496 had normal development.
Girls with central precocious puberty were more likely to report insufficient sleep (adjusted odds ratio [aOR], 1.329; P = .013) and later bedtimes (aOR, 1.576; P = .005) than girls without the condition. No significant link was found between sleep parameters and the risk for central precocious puberty in boys.
When assessing transitions in sleep duration before and after puberty onset, girls with central precocious puberty slept 1 hour less than their peers without the condition until 3 months prior to puberty onset.
Girls with central precocious puberty experienced extreme sleep insufficiency 3.5 years before puberty, whereas boys with the condition slept longer.
IN PRACTICE:
'Insufficient sleep and late bedtime may be critical determinants of CPP. Due to their modifiable nature, we recommend that girls maintain sufficient sleep duration and adhere to earlier sleep times, particularly before puberty,' the authors wrote.
SOURCE:
The study was led by Wen-Yu Lin, MD, of the Department of Family Medicine at the Taipei Medical University Hospital in Taipei, Taiwan. It was published online on July 18, 2025, in the Journal of Adolescent Health.
LIMITATIONS:
The recruitment of participants from urban hospitals may have introduced selection bias. Participants were from families with higher incomes and educational levels, which may not represent the general Asian population. The follow-up period for normally developing boys was not long enough to fully understand the relationship between sleep duration and pubertal development.
DISCLOSURES:
This study was supported by grants from Taipei Medical University Hospital and the National Science and Technology Council. The authors reported having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
CDC warns travelers about chikungunya cases in China as global infections hit 240,000
U.S. health officials are cautioning travelers about a mosquito-borne illness being transmitted in parts of Asia, South America, Africa and the Indian Ocean. Across the globe, the chikungunya virus has sparked 240,000 cases and 90 deaths in 2025, according to the European Centre for Disease Prevention and Control. The virus, which is infecting people through bites from Aedes mosquitoes, has been spreading in China's Guangdong province this summer. Health officials reported the area has seen over 7,000 confirmed cases since June. The U.S. Centers for Disease Control and Prevention (CDC) this month issued a travel notice for the Guangdon province in China, encouraging travelers to practice enhanced precautions. The agency issued the same notices for other countries where outbreaks have been reported, including Bolivia, Kenya, Madagascar, Mauritius, Mayotte, Réunion, Somalia and Sri Lanka. The CDC is also asking U.S. residents to exercise caution when visiting the following countries, which have not yet reported an outbreak but are at elevated risk of exposure: Brazil, Colombia, Mexico, India, Pakistan, Philippines, Thailand and Nigeria. According to the World Health Organization (WHO), 5.6 billion people are at risk of arboviral diseases such as chikungunya. Other widespread arboviruses impacting humans include dengue, Zika and yellow fever. What are the symptoms of chikungunya? Symptoms of the disease include fever, joint pain and swelling, headache, muscle pain and rash, according to the CDC. How long does infection last? The illness typically lasts between two to 12 days after infection. Some patients can experience extreme symptoms and the virus can be fatal. Elderly people, newborns and individuals with underlying medical conditions are at higher risk of medical intervention. Severe complications, including cardiovascular, neurological and multiorgan involvement, may require intensive medical care, according to the WHO. However, more than half of patients will experience symptoms commonly associated with a fever. What treatments are available? There are no known antiviral treatments for the illness. Medications can be used to manage pain and fever. Two chikungunya vaccines have received regulatory approval but are not widely available. In May, federal officials recommended pausing a vaccine in the United States after reports of serious adverse events. The illness was first discovered in Tanzania in 1952, with outbreaks being reported in Africa and Asia, according to the WHO. Since then, the virus has been transmitted to 119 countries. Last year, more than 620,000 and 213 deaths were reported globally, according to the European Centre for Disease Prevention and Control. In what was then dubbed the largest documented outbreak of chikungunya, an estimated several hundred thousand people were affected by "explosive" outbreaks of the virus in the Indian Ocean islands and India, according to a 2008 study. It's estimated that about 60 percent of regional populations were exposed. CDC issues travel notice for Americans The CDC issued a travel warning on Friday, Aug. 1, advising U.S. residents to take enhanced precautions when traveling to China. Most of the country's cases have been reported in the city of Foshan. Last month, Chinese officials held a national conference to discuss treatments for and prevention of the illness. Authorities agreed to continue monitoring the situation and issue early warnings through multiple channels to prevent further spreading, according to China's National Health Commission. Michelle Del Rey is a trending news reporter at USA TODAY. Contact her at mdelrey@ This article originally appeared on USA TODAY: Chikungunya virus cases reported in China prompt CDC travel notice Solve the daily Crossword
Yahoo
24 minutes ago
- Yahoo
JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio's DEX-G2 Blood Test For Early Detection of Gastric Cancer
SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance of the Destinex assay, a novel liquid biopsy that serves as the foundation for Cizzle Bio's DEX-G2 blood-based assay for early detection of gastric cancer—one of the world's deadliest malignancies. The study's findings validate the clinical utility of DEX-G2 as a minimally invasive, clinically actionable tool to detect gastric cancer at its earliest and most treatable stages, when timely intervention can significantly improve outcomes and save lives. The DESTINEX study, conducted at leading cancer centers in Japan and South Korea, evaluated a signature panel of microRNAs derived from exosomes and cell-free serum. The study analyzed 809 serum specimens from 480 participants, including patients with gastric cancer and matched controls. Using machine learning to refine and validate the assay, researchers demonstrated exceptional diagnostic accuracy for early-stage gastric cancer. The study was led by Ajay Goel, Ph.D., AGAF, an internationally recognized leader in cancer biomarker research and the developer of the Destinex assay. Goel also serves as scientific advisor to Cizzle Bio and is chair of the Department of Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center, where he led the development of the Destinex assay into the DEX-G2 blood test that Cizzle Bio is now advancing for near-term commercial launch. "The publication of this study in JAMA Surgery is a critical milestone, not only for our scientific team but also for the future of early gastric cancer detection," said Goel. "By combining the sensitivity of cell-free microRNAs with the specificity of exosomal markers, Destinex—and now DEX-G2—offers a minimally invasive, accessible, and highly accurate method for detecting gastric cancer at a stage when outcomes can be dramatically improved." In the study, the Destinex assay achieved an area under the curve (AUC) of 96.8% in the validation cohort, with a sensitivity of 95.0% for detecting early-stage (pT1) gastric cancer. These findings underscore the assay's strength as a minimally invasive tool for identifying gastric cancer early when it is most curable. The assay achieved high sensitivity and specificity in distinguishing individuals with gastric cancer from those without the disease, confirming its potential not only as a minimally invasive screening tool but also to significantly improve patient outcomes through earlier detection and intervention. A Pressing Clinical Need Gastric cancer is the third leading cause of cancer-related deaths worldwide, mainly due to delayed diagnosis. Globally, more than 60% of gastric cancer cases are diagnosed at advanced stages, when curative treatment is no longer an option and prognosis is poor. Endoscopic screening has helped reduce mortality in high-incidence countries such as Japan and Korea, but its cost, invasiveness, and limited availability make it impractical for widespread use in low-incidence regions. Minimally invasive blood-based tests like DEX-G2 have the potential to fill this gap. The Destinex assay, the scientific basis of DEX-G2, demonstrated outstanding sensitivity and specificity for detecting early-stage (T1) gastric cancer, and its diagnostic performance remained robust across tumor stages and patient subgroups. The study also showed a significant drop in biomarker levels after surgical tumor removal, confirming the assay's tumor specificity. Read the full JAMA Surgery study here: "This study reinforces the scientific credibility and clinical utility of the technology behind DEX-G2," said Bill Behnke, CEO of Cizzle Bio. "We are proud to advance this innovation into clinical practice, where it has the potential to make earlier detection a reality for patients who currently have few options for early detection." From Discovery to Clinical Application Cizzle Bio is advancing its DEX-G2 test, based on the Destinex assay, for near-term commercial deployment in CLIA-certified laboratories. It is intended to support clinicians in detecting gastric cancer earlier, particularly in primary care and gastroenterology settings where endoscopy may not be accessible or practical. The company holds a worldwide exclusive license for DEX-G2 and is actively pursuing commercialization in both U.S. and global markets, with a focus on reaching populations where gastric cancer is often diagnosed too late for curative treatment. About Cizzle Bio Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric cancers. Our goal is to empower patients, equip clinicians, and improve outcomes through innovation, compassion, and life-saving solutions. We hold exclusive licensing rights for our groundbreaking CIZ1B biomarker test in the United States, Canada, and the Caribbean and a worldwide exclusive license for our DEX-G2 biomarker gastric cancer test. Cizzle Bio is commercializing both tests for U.S. clinical Media Contact: Yolanda Heibergeryolanda@ View original content to download multimedia: SOURCE Cizzle Bio


Washington Post
2 hours ago
- Washington Post
Raw milk sickens 21 people in Florida including 6 children
TALLAHASSEE, Fla. — Six children are among 21 people who have E. coli or campylobacter infections after consuming raw milk from a farm in Florida, public health officials said. Seven people have been hospitalized, and at least two of them are suffering severe complications, the Florida Department of Health said Monday. It did not specify if any of the six infected children under 10 are among those being treated in hospitals, nor how many people were infected by E. coli, campylobacter or both bacteria.